Official title: Direct the Federal Trade Commission to conduct a study on the governance of neural data and other related data, and for other purposes.
Introduced September 29, 2025 by Charles Ellis Schumer · Last progress September 29, 2025
The bill would strengthen privacy, consent, and federal governance for neural and related data and improve national-security oversight, but it also introduces compliance costs, regulatory uncertainty, and risks of slowing research or limiting access to beneficial neurotechnologies during implementation.
All Americans — especially consumers, patients (including those with chronic conditions and disabilities), children, and middle- and low-income households — would gain stronger privacy safeguards and clearer consent standards for neural, biometric, and related behavioral data, reducing risks of misuse, discrimination, and covert manipulation.
Federal employees and the public would get binding agency-wide guidance, procurement limits, transparency, purpose-limitation, and opt-in consent requirements that increase control over neural data use and reduce unauthorized collection or misuse in government systems.
Governance and oversight would become clearer and more consistent: the FTC is named as an enforcement commission, the bill creates a centralized OSTP/OMB process, and it mandates a public federal analysis/report within a year to inform policy across agencies.
Businesses that develop or use neurotechnology (and, downstream, consumers) will face new compliance and procurement costs that could be passed on as higher prices, reduced services, or slower product availability.
The bill creates significant regulatory uncertainty and potential overlap (FTC vs. HIPAA/FDA, linking to the NAIIA AI definition, non-binding 'Sense of Congress' language, and likely frequent updates), complicating implementation for regulators, vendors, and users.
Broad restrictions, export controls, procurement prohibitions, or conservative recommendations could slow research collaboration and innovation and limit availability or delay deployment of beneficial neurotechnologies for patients and people with disabilities.
Based on analysis of 5 sections of legislative text.
Directs an FTC study on neural and related data, requires OSTP/OMB guidance on federal uses, and bars federal procurement inconsistent with that guidance one year after OMB issues it.
Requires the Federal Trade Commission to study how neural data and related biometric/behavioral data are collected, used, transferred, and governed, and to publish a public report within one year with recommendations for a regulatory framework and best practices. Directs the Office of Science and Technology Policy, working with FTC and OMB, to issue guidance within 180 days after the FTC report describing permitted/prohibited federal procurement and operational uses of neurotechnology that collects or processes neural or related data; OMB must then issue binding implementation guidance to agencies, and federal agencies are barred from procuring or operating such neurotechnology that is inconsistent with that binding guidance one year after OMB issues it.